Drugs / aNK-DLI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01287104 | Jan 2011 → Jun 2018 | leukemia, lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aNK-DLI | “aNK-DLI were CD3(+)-depleted, CD56(+)-selected lymphocytes” PMID 25452614 ↗ Dec 2014 |
| Modality | Cell therapy | “aNK-DLI were CD3(+)-depleted, CD56(+)-selected lymphocytes” PMID 25452614 ↗ Dec 2014 |
| Route | Intravenous | “natural killer (NK) cells/kg by intravenous (IV) infusion” NCT01287104 ↗ |